XNCR — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-06

• We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases, who have unmet medical needs. Leveraging our XmAb® protein engineering platforms, we rapidly design, engineer and advance pu…

• We advance selected candidates through clinical development, while also partnering with programs to access complementary development and commercialization capabilities. Our portfolio spans early- and mid-stage clinical programs, and our strategic approach emphasizes disciplined portfolio management,…

• Refer to Part I, “Item 1. Business” in our Annual Report on Form 10-K for the year ended December 31, 2025 for a more detailed discussion of our business, technology platforms, pipeline, and key developments.

• We are currently enrolling five clinical studies to evaluate our XmAb drug candidates for patients with many different types of serious diseases.

• XmAb819 (ENPP3 x CD3): XmAb819 is a novel, potential first-in-class, tumor-targeted, T-cell engaging XmAb 2+1 bispecific antibody in development for patients with clear cell renal cell carcinoma (ccRCC). XmAb819 is designed to engage the immune system and activate T cells for highly potent and targe…

Text removed vs the prior filing · source: 10-Q · 2025-11-05

• We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and other serious diseases, who have unmet medical needs. We use our protein engineering capabilities to design new technologies and XmAb® drug candi…

• Our approach to protein design includes engineering Fc domains, the parts of antibodies that interact with multiple segments of the immune system and control antibody structure. The Fc domain is constant and interchangeable among antibodies, and our engineered Fc domains can be readily substituted f…

• We and our partners develop XmAb antibodies and other types of biotherapeutic drug candidates with improved properties and functionality, which can provide innovative approaches to potentially treating disease and clinical benefits over other treatment options. Applications of our protein engineerin…

• Refer to Part I, “Item 1. Business” under “XmAb Bispecific Fc Domain and Multi-Specific Antibody Formats” and “Other XmAb Fc Domains” in the description of our business included in our Annual Report on Form 10-K for the year ended December 31, 2024 for a discussion of our core Fc technology platform…

• We are currently enrolling four clinical studies to evaluate our XmAb drug candidates for patients with many different types of serious diseases.

Text added vs the prior filing · source: 10-Q · 2026-05-06

• Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods …

• Based on such evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2026, the Company’s disclosure controls and procedures were effective at the reasonable assurance level.

• There has been no change in the Company’s internal control over financial reporting during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company regularly evaluates its…

Text removed vs the prior filing · source: 10-Q · 2025-11-05

• Based on such evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that as of such date, the Company’s disclosure controls and procedures were not effective at the reasonable assurance level due to the material weakness related to the design of controls relate…

• The Company’s management is committed to maintaining a strong internal control environment. In response to the material weaknesses identified above, management intends to implement comprehensive remediation actions in a timely manner, under the appropriate oversight of the Audit Committee. These act…

• (1) Material weakness related to the proceeds from the sale of future royalties

• •implementing a more rigorous and structured analysis of non-routine transactions;

• •engaging qualified third-party advisors to assist with highly technical and complex accounting transactions; and

Text added vs the prior filing · source: 10-Q · 2026-05-06

• Legal Proceedings are set forth in the Company’s financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q and are incorporated herein by reference. See Note 7 - Commitments and Contingencies of Notes to Consolidated Financial Statements of Part I, “Item 1. Financial Statements.”

Text removed vs the prior filing · source: 10-Q · 2025-11-05

• For a discussion of material pending legal proceedings, please read Note 7, Commitments and Contingencies to the Company’s consolidated financial statements included in Part I, “Item I. Financial Statements” of this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.

• From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. We are currently a party to an action initiated by Merus N.V. (Merus) in the District of Delaware alleging that our manufacture, use, offer for sale, sale, and/or impor…

Text added vs the prior filing · source: 10-Q · 2026-05-06

• Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading Arrangement

• (1) The trading arrangement permits transactions through and including the earlier to occur of (a) the date that all shares subject to the trading arrangement have been sold and (b) the date listed in the table.